ISU Abxis has the IX factor as Catalyst chooses hemophilia partner
This article was originally published in Scrip
Executive Summary
In another validation of South Korea's expertise in the manufacture of biologic products, the US protease specialist Catalyst Biosciences has struck a partnership with ISU Abxis for the development and commercialization of a next-generation Factor IX product.